Brigatinib-impurities | Pharmaffiliates

brigatinib and its Impurities

Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor. It is a small molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc.. Reference standards of Brigatinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below

Displaying 1 results for brigatinib Impurities
PA 29 44000

Brigatinib - API


  • Catalogue No.:PA 29 44000

  • CAS :


  • Molecular Formula : C29H39ClN7O2P

  • Molecular Weight : 584.09